Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct

M. Tascilar, G. J A Offerhaus, R. Altink, P. Argani, T. A. Sohn, C. J. Yeo, J. L. Cameron, M. Goggins, R. H. Hruban, R. E. Wilentz

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We immunohistochemically labeled 72 biopsy specimens from the extrahepatic biliary tree and pancreas for Dpc4 protein and correlated expression with histologic diagnosis and patient follow-up. Specimens were classified histologically as follows: Nonneoplastic, 35; neoplastic, 22; atypical, 15. Loss of expression of Dpc4 protein was identified in 12 specimens; 11 were histologically diagnostic of carcinoma. The 12th specimen was from a patient whose biopsy specimen initially was diagnosed as "atypical," but clinical follow-up revealed adenocarcinoma. Of the 12 atypical biopsy specimens with intact expression for Dpc4, follow-up later revealed that 10 were adenocarcinoma. Loss of expression of Dpc4 protein was never identified in a benign specimen. Immunohistochemical labeling for the Dpc4 gene product is a specific marker of carcinoma in biopsy specimens of the pancreas and extrahepatic bile ducts and is marginally helpful in classifying atypical specimens. The sensitivity for carcinoma is low. This latter finding is not unexpected, because the DPC4 tumor suppressor gene is inactivated in only about half of pancreatic and biliary malignant neoplasms. Importantly, loss of Dpc4 expression has been reported in in situ carcinomas, suggesting that loss of expression should not be equated with invasive carcinoma.

Original languageEnglish (US)
Pages (from-to)831-837
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume116
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Bile Ducts
Pancreas
Adenocarcinoma
Carcinoma
Biopsy
Genes
Extrahepatic Bile Ducts
Proteins
Carcinoma in Situ
Biliary Tract
Tumor Suppressor Genes
Neoplasms

Keywords

  • Adenocarcinoma
  • Bile duct
  • Dpc4
  • Immunohistochemistry
  • Pancreas
  • Tumor suppressor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. / Tascilar, M.; Offerhaus, G. J A; Altink, R.; Argani, P.; Sohn, T. A.; Yeo, C. J.; Cameron, J. L.; Goggins, M.; Hruban, R. H.; Wilentz, R. E.

In: American Journal of Clinical Pathology, Vol. 116, No. 6, 2001, p. 831-837.

Research output: Contribution to journalArticle

Tascilar, M, Offerhaus, GJA, Altink, R, Argani, P, Sohn, TA, Yeo, CJ, Cameron, JL, Goggins, M, Hruban, RH & Wilentz, RE 2001, 'Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct', American Journal of Clinical Pathology, vol. 116, no. 6, pp. 831-837. https://doi.org/10.1309/WF03-NFCE-7BRH-7C26
Tascilar, M. ; Offerhaus, G. J A ; Altink, R. ; Argani, P. ; Sohn, T. A. ; Yeo, C. J. ; Cameron, J. L. ; Goggins, M. ; Hruban, R. H. ; Wilentz, R. E. / Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. In: American Journal of Clinical Pathology. 2001 ; Vol. 116, No. 6. pp. 831-837.
@article{97bf220e5f2941d1949663c08196b11e,
title = "Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct",
abstract = "We immunohistochemically labeled 72 biopsy specimens from the extrahepatic biliary tree and pancreas for Dpc4 protein and correlated expression with histologic diagnosis and patient follow-up. Specimens were classified histologically as follows: Nonneoplastic, 35; neoplastic, 22; atypical, 15. Loss of expression of Dpc4 protein was identified in 12 specimens; 11 were histologically diagnostic of carcinoma. The 12th specimen was from a patient whose biopsy specimen initially was diagnosed as {"}atypical,{"} but clinical follow-up revealed adenocarcinoma. Of the 12 atypical biopsy specimens with intact expression for Dpc4, follow-up later revealed that 10 were adenocarcinoma. Loss of expression of Dpc4 protein was never identified in a benign specimen. Immunohistochemical labeling for the Dpc4 gene product is a specific marker of carcinoma in biopsy specimens of the pancreas and extrahepatic bile ducts and is marginally helpful in classifying atypical specimens. The sensitivity for carcinoma is low. This latter finding is not unexpected, because the DPC4 tumor suppressor gene is inactivated in only about half of pancreatic and biliary malignant neoplasms. Importantly, loss of Dpc4 expression has been reported in in situ carcinomas, suggesting that loss of expression should not be equated with invasive carcinoma.",
keywords = "Adenocarcinoma, Bile duct, Dpc4, Immunohistochemistry, Pancreas, Tumor suppressor",
author = "M. Tascilar and Offerhaus, {G. J A} and R. Altink and P. Argani and Sohn, {T. A.} and Yeo, {C. J.} and Cameron, {J. L.} and M. Goggins and Hruban, {R. H.} and Wilentz, {R. E.}",
year = "2001",
doi = "10.1309/WF03-NFCE-7BRH-7C26",
language = "English (US)",
volume = "116",
pages = "831--837",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct

AU - Tascilar, M.

AU - Offerhaus, G. J A

AU - Altink, R.

AU - Argani, P.

AU - Sohn, T. A.

AU - Yeo, C. J.

AU - Cameron, J. L.

AU - Goggins, M.

AU - Hruban, R. H.

AU - Wilentz, R. E.

PY - 2001

Y1 - 2001

N2 - We immunohistochemically labeled 72 biopsy specimens from the extrahepatic biliary tree and pancreas for Dpc4 protein and correlated expression with histologic diagnosis and patient follow-up. Specimens were classified histologically as follows: Nonneoplastic, 35; neoplastic, 22; atypical, 15. Loss of expression of Dpc4 protein was identified in 12 specimens; 11 were histologically diagnostic of carcinoma. The 12th specimen was from a patient whose biopsy specimen initially was diagnosed as "atypical," but clinical follow-up revealed adenocarcinoma. Of the 12 atypical biopsy specimens with intact expression for Dpc4, follow-up later revealed that 10 were adenocarcinoma. Loss of expression of Dpc4 protein was never identified in a benign specimen. Immunohistochemical labeling for the Dpc4 gene product is a specific marker of carcinoma in biopsy specimens of the pancreas and extrahepatic bile ducts and is marginally helpful in classifying atypical specimens. The sensitivity for carcinoma is low. This latter finding is not unexpected, because the DPC4 tumor suppressor gene is inactivated in only about half of pancreatic and biliary malignant neoplasms. Importantly, loss of Dpc4 expression has been reported in in situ carcinomas, suggesting that loss of expression should not be equated with invasive carcinoma.

AB - We immunohistochemically labeled 72 biopsy specimens from the extrahepatic biliary tree and pancreas for Dpc4 protein and correlated expression with histologic diagnosis and patient follow-up. Specimens were classified histologically as follows: Nonneoplastic, 35; neoplastic, 22; atypical, 15. Loss of expression of Dpc4 protein was identified in 12 specimens; 11 were histologically diagnostic of carcinoma. The 12th specimen was from a patient whose biopsy specimen initially was diagnosed as "atypical," but clinical follow-up revealed adenocarcinoma. Of the 12 atypical biopsy specimens with intact expression for Dpc4, follow-up later revealed that 10 were adenocarcinoma. Loss of expression of Dpc4 protein was never identified in a benign specimen. Immunohistochemical labeling for the Dpc4 gene product is a specific marker of carcinoma in biopsy specimens of the pancreas and extrahepatic bile ducts and is marginally helpful in classifying atypical specimens. The sensitivity for carcinoma is low. This latter finding is not unexpected, because the DPC4 tumor suppressor gene is inactivated in only about half of pancreatic and biliary malignant neoplasms. Importantly, loss of Dpc4 expression has been reported in in situ carcinomas, suggesting that loss of expression should not be equated with invasive carcinoma.

KW - Adenocarcinoma

KW - Bile duct

KW - Dpc4

KW - Immunohistochemistry

KW - Pancreas

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=17944382039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944382039&partnerID=8YFLogxK

U2 - 10.1309/WF03-NFCE-7BRH-7C26

DO - 10.1309/WF03-NFCE-7BRH-7C26

M3 - Article

VL - 116

SP - 831

EP - 837

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -